Understanding trans platinum complexes as potential antitumor drugs beyond targeting DNA

Coordination compounds in cancer: Past, present and perspectives

“…Interestingly, the cisplatin analogues show a better tumour regression than cisplatin alone in human breast cancer estrogens-receptor positive mouse xenograft model (Themsche et al, 2009). However, the substitution of cisplatin ligands has not extended significantly the range of applicability of platinum-based drugs in cisplatin-resistant cancers probably because of the use of only one structural motif (Quiroga, 2012). Therefore, the research focused on platinum complexes with different geometry (e.g., trans-Pt(II) complexes) and oxidation state (e.g., Pt(IV) complexes).…”

Design and Biological Evaluation of New Platinum(II) Complexes Bearing Ligands with DNA-Targeting Ability

“…NMR spectra were acquired on a Bruker 300 spectrometer, running at 300, 75, and 64.5 MHz for 1 H, 13 29.84 for 13 C NMR). 13 C NMR spectra were acquired on a broad-band decoupled mode.…”

Crystal structure and antimicrobial activity of a transplatin adduct of N,N′-dimethylthiourea, trans-[Pt(NH3)2(dmtu)2]Cl2

“…Trans-Diamminedichloridoplatinum(II) (transplatin) on the other hand was found to be inactive against cancer cells due to its inability to form 1,2-intrastrand cross-links because of steric constraints [1][2][3][4][5][6][7][8][9][10][11]. However, several transplatin analogues composed of iminoethers, aliphatic amines, and heterocyclic ligands are known to exhibit cytotoxic effects in a number of tumor cell lines including those resistant to cisplatin [11][12][13][14][15][16]. Trans compounds mainly form N7-guanine monofunctional adducts [2,8,10,17] and interstrand cross-links between the N7-nitrogen of guanine and the N3-nitrogen of its basepaired cytosine [2,8,10,18].…”